Derek J. Maetzold

Founder, President, Chief Executive Officer (CEO) at Castle Biosciences Inc

Board

Since September 2007

Age

63 years

Education

Holds a B.S. degree in Biology from George Mason University and has completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.

Tenure

Founded CSTL in September 2007 and has served as its President and Chief Executive Officer (CEO) since its inception.

Also at Castle Biosciences Inc

Frank Stokes

Chief Financial Officer

KMO

Kristen M. Oelschlager

Chief Operating Officer

TWJ

Tobin W. Juvenal

Chief Commercial Officer

About

The executive holds a strong academic background, having earned a B.S. degree in Biology from George Mason University and completed further studies at the University of Calgary Health Sciences Center as well as the MBA program at the University of California, Riverside.

He founded CSTL in September 2007 and has served as its President and Chief Executive Officer (CEO) since inception, contributing significantly to the development and commercialization of diagnostic tests, particularly in the areas of oncology and dermatology.

Prior to launching CSTL, he gained extensive leadership experience in the pharmaceutical and healthcare sectors through roles at organizations such as Encysive Pharmaceuticals, Schering-Plough Corporation, Integrated Communications, Amylin Pharmaceuticals, and Sandoz Pharmaceuticals, while also contributing his expertise as a board member for entities including PreludeDx and IMPACT Melanoma.

$CSTL Performance Under Derek J. Maetzold

Past Roles

Organization	Role	Date Range	Details
Encysive Pharmaceuticals	Leadership Role	N/A	Contributed to the discovery, development, and commercialization of diagnostic tests and co-invented technologies
Schering-Plough Corporation (now Merck)	Leadership Role	N/A	Role not detailed
Integrated Communications	Leadership Role	N/A	Role not detailed
Amylin Pharmaceuticals	Leadership Role	N/A	Role not detailed
Sandoz Pharmaceuticals (now a division of Novartis)	Leadership Role	N/A	Role not detailed

External Roles

Organization	Role	Date Range	Details
PreludeDx	Director	N/A	Active role outside CSTL
Coalition for 21st Century Medicine	Director	N/A	Active role outside CSTL
IMPACT Melanoma	Director	N/A	Active role outside CSTL

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$686,400	Annual	Fixed annual cash compensation; increased by 4.0% from $660,000 in 2022
401(k) Matching Contributions	$18,300	Per contribution period	Matches 100% of up to 6% of eligible compensation; maximum match for 2023 was $19,800
Financial Advisory Services	$7,934	Annual	Reimbursement for financial advisory services provided in 2023

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation

Metric	Value	Citation
Performance Basis	Corporate Performance Goals (100% weighting)
Threshold Level	55.0%
Target Level	100%
Maximum Level	172.5%
Actual Corporate Performance	137.0%
Base Salary Used for Calculation	$686,400
Target Bonus Percentage	95% of base salary
Target Bonus Amount	$652,080
Actual Bonus Earned	$893,350
Vesting Schedule	None (cash bonus, no vesting)	N/A
Grant Date / Fair Value / Stock Price	N/A	N/A
Evaluation Period	2023